Abstract
BackgroundDysregulation of the long non-coding RNA small nucleolar RNA host gene 16 (lncRNA SNHG6) has been found in multiple cancers. However, a definite conclusion on the clinical value of lncRNA SNHG6 expression in human cancers has not been determined. The purpose of the present meta-analysis was to comprehensively elucidate the association between SNHG6 expression and clinical outcomes in cancers.MethodsA systematic search was performed through the PubMed, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Wangfang databases for relevant studies. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were collected to estimate the prognostic value, and the odds ratios (ORs) with 95% CIs were used to evaluate the relationship between lncRNA SNHG6 expression and clinicopathological features, including tumor invasion depth, lymph node metastasis (LNM), distance metastasis (DM), and TNM stage.ResultsIn total, 914 patients from 13 studies were included in this meta-analysis. The pooled results suggested that evaluated SNHG6 expression could predict an unfavorable overall survival (OS) (HR = 2.04, 95% CI:1.56–2.52) with no heterogeneity (I2 = 0.0%, p = 0.996). Subgroup analysis indicated a significant association between high SNHG6 expression and shorter OS in those studies with digestive system cancers (HR = 2.05, 95% CI: 1.47–2.62), or with sample size < 70 (HR = 2.70, 95% CI: 1.29–4.11), or with multivariate analysis (HR = 2.04, 95% CI: 1.44–2.64). Moreover, elevated SNHG6 expression was positively associated with tumor invasion depth (OR = 1.76, 95% CI: 1.18–2.63), LNM (OR = 1.60, 95% CI: 1.18–2.17), DM (OR = 1.90, 95% CI: 1.37–2.64) and advanced TNM stage (OR = 1.88, 95% CI: 1.36–2.60) in patients with cancers.ConclusionsHigh lncRNA SNHG6 expression was correlated with tumor invasion depth, LNM, DM, and advanced TNM stage, suggesting that SNHG6 may serve as a promising prognostic biomarker of human cancers.
Highlights
Dysregulation of the long non-coding RNA small nucleolar RNA host gene 16 has been found in multiple cancers
Growing evidence has demonstrated that Long non-coding RNAs (lncRNAs) can be recognized as tumor-specific prognostic predictors for some cancers, and recent meta-analyses have suggested several lncRNAs correlated with prognosis and chinicopathological features as candidates for precise prognosis prediction of cancers, such as DANCR [7], CRNDE [8] and MVIH [9]
Inclusion criteria were as follows: 1) studies reporting the relationship between lncRNA small nucleolar RNA host gene 16 (SNHG6) expression and clinicopathological characteristics and prognosis, 2) human cancer, 3) patients were grouped based on the level of SNHG6 expression, 4) studies providing available data for extracting or calculating hazard ratios (HRs) and 95%95% confidence interval (CI) for overall survival (OS)
Summary
Dysregulation of the long non-coding RNA small nucleolar RNA host gene 16 (lncRNA SNHG6) has been found in multiple cancers. A definite conclusion on the clinical value of lncRNA SNHG6 expression in human cancers has not been determined. The purpose of the present meta-analysis was to comprehensively elucidate the association between SNHG6 expression and clinical outcomes in cancers. Numerous studies have suggested that lncRNAs play vital roles in various physiological and pathological process of cancers, including cell proliferation, migration, invasion, and metabolism by functioning as oncogene or tumor suppressor [4,5,6]. Given the discrete outcomes and limited sample size in current studies, we performed this meta-analysis to evaluate the potential value of SNHG6 as a promising prognostic biomarker in human cancers
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
